Argenx Se (1AEA) Stock Price & Analysis
1AEA Stock Chart & Stats
- Day’s Range
- EUR 760.00 - EUR 805.00
- 52-Week Range
- EUR 560.00 - EUR 920.00
- Previous Close
- EUR 790.00
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 51.25B
- Enterprise Value
- EUR 54.62B
- Total Cash (Recent Filing)
- EUR 5.18B
- Total Debt (Recent Filing)
- EUR 47.00M
- Price to Earnings (P/E)
- 43.0
- Beta
- 0.25
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- 7.17
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Margin Expansion
Rapid revenue growth combined with exceptionally strong margins indicates substantial commercial traction and operating leverage. If product adoption and geographic expansion continue, the resulting profitability can fund additional development internally while strengthening the company’s competitive position.
Exceptional Balance Sheet
Minimal leverage gives argenx significant financial flexibility to fund research, acquisitions, launches, and infrastructure without depending heavily on borrowing. A large equity and asset base also improves resilience if clinical or commercial outcomes create periods of higher investment.
Commercial And Pipeline Breadth
The established VYVGART franchise provides a commercial foundation while multiple clinical programs and potential label expansions create several avenues for future growth. This breadth reduces reliance on a single near-term catalyst and supports a durable multi-indication strategy.
Bears Say
Uneven Cash Conversion
Although cash generation improved materially in 2025, the prior multi-year record remains uneven and operating cash flow did not fully match reported earnings. Sustained profitability therefore remains important to ensure growth investments can continue without renewed reliance on external capital.
Sharp Expense Increase
The planned spending step-up reflects meaningful investment in the pipeline, commercial infrastructure, and Forte, but it raises execution requirements. If upcoming launches or development programs progress more slowly than expected, higher fixed investment could pressure margins and reduce operating leverage.
Clinical Program Setbacks
These setbacks demonstrate that the pipeline carries material development risk despite strong progress elsewhere. Additional confirmatory work for dermatomyositis can delay potential expansion, while the Sjögren’s discontinuation removes one avenue for future indication growth.
Argenx Se News
Argenx Advances Empasiprubart Into Phase 2 for Guillain-Barré: What Investors Should Watch
Argenx ($ARGX) announced an update on their ongoing clinical study. Argenx (ARGX) has launched a new Phase 2 study called “A Phase 2, Randomized, Double-Blinded, Placebo-Controlled Study to Assess the
1AEA FAQ
What was Argenx Se’s price range in the past 12 months?
What is Argenx Se’s market cap?
When is Argenx Se’s upcoming earnings report date?
How were Argenx Se’s earnings last quarter?
Is Argenx Se overvalued?
Does Argenx Se pay dividends?
What is Argenx Se’s EPS estimate?
How many shares outstanding does Argenx Se have?
What happened to Argenx Se’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Argenx Se?
What is the TipRanks Smart Score and how is it calculated?
Argenx Se Stock Smart Score
Company Description
Argenx Se
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Karen Massey
- Employees
- 1,863
- Website
- www.argenx.com
- Address
- Laarderhoogtweg 25, Amsterdam, NH, 1101 EB, NL
Argenx Se (1AEA) Earnings & Revenues
1AEA Company Deck
1AEA Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, supported by 54% year-over-year product sales growth, continued momentum in both MG and CIDP, positive ALKIVIA and FB102 data, a broadening pipeline and expectations for up to five potential launches in 2027. The main challenges were the dermatomyositis confirmatory-trial requirement, the Sjögren's futility outcome, elevated planned operating expenses and limited formal revenue guidance, but these issues were outweighed by the company's commercial performance, financial strength and pipeline progress.
View all DE:1AEA earnings summaries1AEA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 2 | 3 |
| Technical Analysis | 4 | 2 | 3 |
| Moving Averages | 12 | 0 | 0 |
